Suppr超能文献

多电极射频球囊导管行肺静脉隔离术治疗阵发性心房颤动的安全性、有效性和生活质量:SHINE 研究 1 年结果。

Safety, effectiveness, and quality of life following pulmonary vein isolation with a multi-electrode radiofrequency balloon catheter in paroxysmal atrial fibrillation: 1-year outcomes from SHINE.

机构信息

Department of Cardiology, St. Bartholomew's Hospital, W Smithfield, London EC1A 7BE, UK.

Monzino Cardiology Center, University of Milan, Via Carlo Parea, 4, 20138 Milano MI, Italy.

出版信息

Europace. 2021 Jun 7;23(6):851-860. doi: 10.1093/europace/euaa382.

Abstract

AIMS

To evaluate the safety and effectiveness of a compliant multi-electrode radiofrequency balloon catheter (RFB) used with a multi-electrode diagnostic catheter for pulmonary vein isolation (PVI).

METHODS AND RESULTS

This prospective, multicentre, single-arm study was conducted at six European sites and enrolled patients with symptomatic paroxysmal atrial fibrillation. The primary effectiveness endpoint was entrance block in treated pulmonary veins (PVs) after adenosine/isoproterenol challenge. The primary safety endpoint was the occurrence of primary adverse events (PAEs) within 7 days. Cerebral magnetic resonance imaging and neurological assessments were performed pre- and post-ablation in a subset of patients. Atrial arrhythmia recurrence was assessed over 12 months via transtelephonic and Holter monitoring. Quality of life was assessed by the Atrial Fibrillation Effect on Quality of Life (AFEQT) questionnaire. Of 85 patients undergoing ablation per study protocol, PV entrance block was achieved in all (one PV required touch-up with a focal catheter). Acute reconnection of ≥1 PVs after adenosine/isoproterenol challenge was observed in 9.3% (30/324) of PVs ablated. Post-ablation, silent cerebral lesions were detected in 9.7% (3/31) of patients assessed, all of which was resolved at 1-month follow-up. One patient experienced a PAE (retroperitoneal bleed). Freedom from documented symptomatic and all arrhythmia was 72.2% and 65.8% at 12 months. Four patients (4.7%) underwent repeat ablation. Significant improvements in all AFEQT subscale scores were seen at 6 and 12 months.

CONCLUSION

PVI with the novel RFB demonstrated favourable safety and effectiveness, with low repeat ablation rate and clinically meaningful improvement in quality of life.

CLINICALTRIALS.GOV REGISTRATION NUMBER: NCT03437733.

摘要

目的

评估一种新型顺应性多电极射频球囊导管(RFB)联合多电极诊断导管进行肺静脉隔离(PVI)的安全性和有效性。

方法和结果

这项前瞻性、多中心、单臂研究在欧洲的 6 个中心进行,纳入了有症状阵发性心房颤动的患者。主要有效性终点是腺苷/异丙肾上腺素激发后治疗肺静脉(PV)的入口阻滞。主要安全性终点是 7 天内主要不良事件(PAEs)的发生。在部分患者中,在消融前和消融后进行了脑磁共振成像和神经学评估。通过远程和动态心电图监测评估 12 个月内的房性心律失常复发情况。通过心房颤动对生活质量的影响(AFEQT)问卷评估生活质量。根据研究方案,85 例患者接受消融治疗,所有患者均实现了 PV 入口阻滞(1 条 PV 需要使用点状导管进行补点消融)。腺苷/异丙肾上腺素激发后,观察到 9.3%(30/324)消融的 PV 出现≥1 条 PV 的急性再连接。消融后,在 31 例接受评估的患者中有 9.7%(3/31)检测到无症状性脑内病变,所有病变在 1 个月随访时均得到解决。1 例患者发生 PAE(腹膜后出血)。12 个月时,有记录的症状性和所有心律失常的无复发率分别为 72.2%和 65.8%。4 例患者(4.7%)接受了重复消融。在 6 个月和 12 个月时,所有 AFEQT 亚量表评分均显著改善。

结论

新型 RFB 行 PVI 具有良好的安全性和有效性,复发消融率低,生活质量显著提高。

临床试验注册

NCT03437733。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/663a/8186540/bd09ea7d105d/euaa382f5.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验